Since novel imaging modalities based on prostate-specific membrane antigen (PSMA) are entering clinical routine, it is becoming evident that most of the high-risk localized PCa patients treated by RP or radiotherapy plus ADT do not, in fact, have localized but rather oligometastatic PCa [18,19]. Here, FOLH1 is linked to posterior cortical atrophy.